However, five CML patients (L1, L5, L13, L19, and L20) showed major molecular response (MMR) reduction of BCR-ABL transcripts less than 0.1%, but CML patients L7, L11, L12, L13, L15, L16, L17, and L22 showed no response against the drug (Figure 9). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.